Early Vascular Risk Factor Modification in Type 1 Diabetes

2005 ◽  
Vol 352 (4) ◽  
pp. 408-409 ◽  
Author(s):  
Bruce A. Perkins ◽  
Vera Bril
Author(s):  
Joanne A. Byars ◽  
Ricardo E. Jorge

Vascular cognitive impairment (VCI)—vascular dementia (VasD) in its severe form—is cognitive impairment due to cerebral ischaemic or haemorrhagic disease. VasD is the second most common cause of dementia in the United States. VCI and Alzheimer’s disease can coexist and synergistically worsen each other. Clinical features of VCI can vary, depending on which areas of the brain the vascular pathology affects. Individuals without a history of clinical stroke can still have VCI; small-vessel cerebrovascular disease can present as an insidious cognitive decline, rather than an abrupt functional change. Neuroimaging plays a key role in diagnosing VCI and distinguishing it from other aetiologies of cognitive impairment. Aggressive vascular risk factor modification helps prevent VCI and improves outcomes in VCI, and represents the most important intervention for this condition. Early detection of VCI maximizes the effectiveness of vascular risk factor modification. Cholinesterase inhibitors and memantine may offer some cognitive benefit in VCI.


Circulation ◽  
2013 ◽  
Vol 127 (suppl_12) ◽  
Author(s):  
Karen C Albright ◽  
Rikki M Tanner ◽  
Amelia K Boehme ◽  
T. Mark Beasley

Background: With a US prevalence of 795,000 strokes per year and stroke recurrence rates up to 20%, the objective of this study was to determine the prevalence of prescription medication use for secondary stroke prevention and vascular risk factor modification among noninstitutionalized US adults and compare medication use in Whites and Blacks. Methods: A cross-sectional study was performed as part of the National Health and Nutrition Examination Survey (NHANES) 2009-2010. Demographic, disease, and prescription medication use were obtained via a standardized interview. Participants were asked if they had ever been told by a health professional that they had hypertension, diabetes, high cholesterol, or a stroke. Additionally, participants were asked if they had taken or used any prescription medicine in the past month as well as the names of each prescription medication. Statistical analyses used NHANES sample weights to provide prevalence estimates for the US population. Results: Among 11,375 participants (21% Black, 47.6% men, age 20-80), medication use for secondary stroke prevention and vascular risk factors remained low (Table 1). Participants who reported taking either an antiplatelet agent or an anticoagulant with a history of stroke remained low (7.9% Whites vs 6.2% Blacks). More Blacks with hypertension reported taking blood pressure lowering agents (38.9 vs 36.1% Whites). Diabetic medication use was lower in Blacks reporting a history of diabetes (24.5 vs 25.7% Whites). Medication use rates were lowest in participants reporting high cholesterol, with more Whites reporting use of a cholesterol lowering medication (19.3 vs 14.6%; p<0.001). Conclusion: Despite the prevalence of stroke and vascular risk factors, only a small proportion of people at risk are on medications for secondary stroke prevention and vascular risk factor modification. Overall, Blacks were taking fewer medications for secondary stroke prevention and vascular risk factor modification with the exception of anti-hypertension medication.


1991 ◽  
Vol 8 (4) ◽  
pp. 334-337 ◽  
Author(s):  
K. Nørgaard ◽  
B. Feldt-Rasmussen ◽  
T. Deckert

Sign in / Sign up

Export Citation Format

Share Document